Standout Papers

Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients Wit... 2000 2026 2008 2017 923
  1. Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma (2000)
    Mark R. Middleton, Jean‐Jacques Grob et al. Journal of Clinical Oncology
  2. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study (2009)
    Jedd D. Wolchok, Bart Neyns et al. The Lancet Oncology
  3. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) (2017)
    Jacob Schachter, Antoni Ribas et al. The Lancet
  4. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study (2019)
    Caroline Robert, Antoni Ribas et al. The Lancet Oncology
  5. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study (2019)
    Georgina V. Long, Reinhard Dummer et al. The Lancet Oncology
  6. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial (2017)
    Michael A. Davies, Philippe Saïag et al. The Lancet Oncology
  7. Prevalence and factors associated with hidradenitis suppurativa: Results from two case-control studies (2008)
    J. Revuz, Florence Canouï‐Poitrine et al. Journal of the American Academy of Dermatology
  8. Melanoma (2015)
    Dirk Schadendorf, David E. Fisher et al. Nature Reviews Disease Primers
  9. Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline (2015)
    Célèste Lebbé, Jürgen C. Becker et al. European Journal of Cancer
  10. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline (2015)
    Alexander Stratigos, Claus Garbe et al. European Journal of Cancer
  11. Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study (2014)
    Sarbjit S. Saini, Carsten Bindslev‐Jensen et al. Journal of Investigative Dermatology

Immediate Impact

44 by Nobel laureates 13 from Science/Nature 146 standout
Sub-graph 1 of 20

Citing Papers

Activatable Photosensitizers: From Fundamental Principles to Advanced Designs
2025 Standout
Cutaneous melanoma
2023 Standout
45 intermediate papers

Works of Jean‐Jacques Grob being referenced

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
2019 Standout
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
2017 Standout
and 30 more

Author Peers

Author Last Decade Papers Cites
Jean‐Jacques Grob 11782 6418 3417 4670 556 21.8k
Jeffrey E. Gershenwald 19181 9668 3004 4899 278 24.9k
Ryuzo Ueda 6050 7194 1044 5680 655 22.7k
Claus Garbe 20753 14755 6161 6876 730 33.4k
Jürgen C. Becker 9372 5249 1491 5577 460 19.7k
Alexander M.M. Eggermont 18119 9231 1784 6568 386 25.1k
Martín C. Mihm 20050 9078 7452 8140 451 33.8k
Timothy M. Johnson 9456 3995 2998 1313 224 14.5k
Charles M. Balch 19525 8057 3128 7666 304 30.9k
Paul A. Bunn 16600 9788 2446 7023 487 34.7k
Stephen J. Forman 15823 7901 600 8877 850 35.1k

All Works

Loading papers...

Rankless by CCL
2026